98%
921
2 minutes
20
Background: Although oncology clinical practice guidelines recognize the need and benefits of exercise, the implementation of these services into cancer care delivery remains limited. We developed and evaluated the impact of a clinically integrated 8-week exercise and education program (CaRE@ELLICSR).
Methods: We conducted a mixed methods, prospective cohort study to examine the effects of the program. Each week, participants attended a 1-h exercise class, followed by a 1.5-h education session. Questionnaires, 6-min walk tests (6MWT), and grip strength were completed at baseline (T0), 8 weeks (T1), and 20 weeks (T2). Semi-structured interviews were conducted with a sub-sample of participants about their experience with the program.
Results: Between September 2017 and February 2020, 277 patients enrolled in the program and 210 consented to participate in the research study. The mean age of participants was 55 years. Participants were mostly female (78%), white/Caucasian (55%) and half had breast cancer (50%). Participants experienced statistical and clinically meaninful improvements from T0 to T1 in disability, 6MWT, grip strength, physical activity, and several cancer-related symptoms. These outcomes were maintained 3 months after program completion (T2). Qualitative interviews supported these findings and three themes emerged from the interviews: (1) empowerment and control, (2) supervision and internal program support, and (3) external program support.
Conclusions: This study demonstrates the impact of overcoming common organizational barriers to deliver exercise and rehabilitation as part of routine care. CaRE@ELLICSR demonstrated clinically meaningful improvements in patient-reported and functional outcomes and was considered beneficial and important by participants for their recovery and wellbeing.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923049 | PMC |
http://dx.doi.org/10.1002/cam4.7009 | DOI Listing |
J Clin Invest
September 2025
Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, United States of America.
B-lymphocytes play major adaptive immune roles, producing antibody and driving T-cell responses. However, how immunometabolism networks support B-cell activation and differentiation in response to distinct receptor stimuli remains incompletely understood. To gain insights, we systematically investigated acute primary human B-cell transcriptional, translational and metabolomic responses to B-cell receptor (BCR), Toll-like receptor 9 (TLR9), CD40-ligand (CD40L), interleukin-4 (IL4) or combinations thereof.
View Article and Find Full Text PDFCell Biochem Biophys
September 2025
School of Natural Sciences, Macquarie University Sydney, Macquarie Park, NSW, Australia.
J Nephrol
September 2025
Institute of Nephrology, Madras Medical College, Chennai, India.
Background: IgA nephropathy is a disease with a highly variable natural history, for which there is an increasing understanding of the role of complement activation in its pathogenesis and progression. We aimed to assess the clinical and prognostic implications of C4d staining in the kidney biopsy of IgA nephropathy patients.
Methods: This was a retrospective observational study wherein the medical records of IgA nephropathy patients were reviewed and baseline characteristics, kidney biopsy findings, treatment response and follow-up data were noted.
J Neurooncol
September 2025
Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Rationale And Objectives: Double expression lymphoma (DEL) is an independent high-risk prognostic factor for primary CNS lymphoma (PCNSL), and its diagnosis currently relies on invasive methods. This study first integrates radiomics and habitat radiomics features to enhance preoperative DEL status prediction models via intratumoral heterogeneity analysis.
Materials And Methods: Clinical, pathological, and MRI imaging data of 139 PCNSL patients from two independent centers were collected.
J Neurooncol
September 2025
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.
View Article and Find Full Text PDF